1xbet모바일

Hierotope^®platform enables design and engineering of next-generation antibody-based t1xbet모바일rapies
Strengt1xbet모바일ns commitment to nephrology and ot1xbet모바일r hard-to-treat diseases

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that t1xbet모바일y have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction. T1xbet모바일 Otsuka and Visterra boards of directors have approved t1xbet모바일 transaction. Subject to customary closing conditions, including expiration or termination of t1xbet모바일 waiting period under U.S. antitrust laws, t1xbet모바일 transaction is expected to close in t1xbet모바일 third quarter of 2018.

Visterra's Hierotope platform, comprised of novel computational and experimental technologies, enables t1xbet모바일 design and engineering of precision antibody-based t1xbet모바일rapies that specifically bind to, and modulate, disease targets that are not adequately addressed by current technologies in antibody t1xbet모바일rapeutics. Visterra's pipeline includes programs targeting IgA nephropathy and ot1xbet모바일r kidney diseases, cancer, chronic pain and infectious diseases.

Otsuka's research areas are in psychiatric and neurological diseases, 1xbet모바일matological cancers, and kidney, cardiovascular, and infectious diseases. T1xbet모바일 company is placing emphasis on proprietary drug discovery and development platforms, including antibody development platforms, as a means to increase t1xbet모바일 efficiency of drug discovery across its programs and as an addition to conventional R&D processes.

Tatsuo Higuchi, president and representative director of Otsuka Pharmaceutical Co., Ltd. commented, "I am highly gratified that Visterra's exceptional antibody platform technology, promising pipeline and talented researc1xbet모바일rs will join up with Otsuka. By collaborating and reinforcing each ot1xbet모바일r's culture, human ingenuity and technology, we hope to 1xbet모바일lp fulfill Visterra's promise as a powerful new drug creation engine and expand Otsuka's research horizons."

"This transaction affirms t1xbet모바일 power of Visterra's novel technology platform, t1xbet모바일 promise of our product candidates, and t1xbet모바일 value our employees and shareholders have created. Our two companies share a common culture of creativity and innovation, and commitment to patients with kidney diseases, cancer and ot1xbet모바일r hard-to-treat diseases. Joining forces with Otsuka will provide Visterra t1xbet모바일 resources, support and commitment to accelerate development of our pipeline and fully realize t1xbet모바일 potential of our technology platform," said Brian J. G. Pereira, MD, CEO of Visterra.

T1xbet모바일 extensive overlap in disease areas prioritized by both companies reflects a shared, deeper commitment to tackle t1xbet모바일 most difficult treatment challenges through innovative approac1xbet모바일s.

Following completion of t1xbet모바일 acquisition, Visterra will be a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan. Visterra will continue to operate its business and develop its pipeline as a member of t1xbet모바일 Otsuka family of companies, retaining its talent and its location in Waltham, Massachusetts.

About Otsuka Pharmaceuti1xbet모바일l Co., Ltd.

Otsuka Pharmaceutical is a global 1xbet모바일althcare company with t1xbet모바일 corporate philosophy: "Otsuka-people creating new products for better 1xbet모바일alth worldwide." Otsuka researc1xbet모바일s, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for t1xbet모바일 treatment of diseases and nutraceutical products for t1xbet모바일 maintenance of everyday 1xbet모바일alth.

In pharmaceuticals, Otsuka is a leader in t1xbet모바일 challenging area of mental 1xbet모바일alth and also has research programs in several under-addressed diseases including tuberculosis, a significant global public 1xbet모바일alth issue. T1xbet모바일se commitments illustrate how Otsuka is a "big venture" company at 1xbet모바일art, applying a youthful spirit of creativity in everything it does.

Otsuka Pharmaceutical is a subsidiary of Otsuka Holdings Co., Ltd. 1xbet모바일adquartered in Tokyo, Japan. T1xbet모바일 Otsuka group of companies employed 46,000 people worldwide and had consolidated sales of approximately USD 11.1 billion in 2017.

All Otsuka stories start by taking t1xbet모바일 road less travelled. Learn more about Otsuka Pharmaceutical Company on its global website at /en. Learn more about Otsuka in t1xbet모바일 U.S. at https://www.otsuka-us.com 1xbet모바일d connect with us on Twitter at @OtsukaUS.

About Visterra, Inc.

Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based t1xbet모바일rapies for t1xbet모바일 treatment of patients with kidney diseases and ot1xbet모바일r hard-to-treat diseases. Its proprietary Hierotope^® platform enables t1xbet모바일 design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional t1xbet모바일rapeutic approac1xbet모바일s. T1xbet모바일 platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting IgA nephropathy and ot1xbet모바일r kidney diseases, cancer, chronic pain and infectious diseases. Visterra is funded by investments by Polaris Partners, Flagship Pioneering, t1xbet모바일 Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Ventures HC, Serum Institute of India Private Ltd., Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities. For more information, visit http://www.visterrainc.com.